Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.
Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.
Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.
Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.
Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of
Amgen will host a live webcast on Sept. 16, 2021, at 8:30 a.m. ET, featuring David M. Reese, M.D., discussing clinical data on the KRASG12C inhibitor LUMAKRAS™ (sotorasib) alongside Vectibix® (panitumumab) during the ESMO 2021 Congress. The event is open to the investment community, media, and the public, accessible via Amgen's website. Archived playback will be available for at least 90 days post-event. Founded in 1980, Amgen is a leading biotechnology firm focused on innovative therapeutics for serious diseases.
Kyowa Kirin Co., Ltd. announced detailed data from a Phase 2 study of KHK4083/AMG 451, a potential first-in-class anti-OX40 monoclonal antibody for treating atopic dermatitis. The findings will be highlighted at the EADV Congress from September 29 to October 2, 2021. The study involved 274 patients, assessing its efficacy and safety through the Eczema Area and Severity Index (EASI) over 16 weeks. KHK4083/AMG 451 leverages advanced POTELLIGENT technology to enhance immune responses and is a collaborative development with Amgen, which will lead global commercialization outside of Japan.
Amgen (NASDAQ: AMGN) announced new data from its inflammation pipeline will be presented at the EADV 30th Congress from Sept. 29 to Oct. 2, 2021. Key highlights include late-breaking results from a Phase 2 study of AMG 451/KHK4083, a potential treatment for moderate-to-severe atopic dermatitis, and new data from the Phase 3 ADVANCE trial on Otezla's efficacy for plaque psoriasis. Amgen aims to share insights into innovative treatments for patients with severe skin conditions, reflecting its commitment to dermatologic diseases advancement.
Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 19th Annual Global Healthcare Conference on September 14, 2021, at 2:45 p.m. ET. CEO Robert A. Bradway will lead the presentation, which will be available for live streaming online, accessible to media, investors, and the public. The webcast can be found on Amgen's official website under the Investors section and will be archived for 90 days post-event. Amgen is known for its focus on discovering and developing innovative therapies aimed at unmet medical needs.
Amgen announced new data from the Phase 2 CodeBreaK 100 trial of LUMAKRAS (sotorasib), the first KRASG12C inhibitor approved in the U.S. for treating KRAS G12C-mutated non-small cell lung cancer (NSCLC). Results showed a 77.5% disease control rate and median overall survival of 8.3 months in patients with stable brain metastases. Furthermore, Amgen is advancing the investigational therapy acapatamab in NSCLC. The findings were presented at the virtual 2021 World Conference on Lung Cancer, highlighting Amgen's commitment to developing targeted therapies for challenging cancers.
Amgen announced groundbreaking results from the NAVIGATOR Phase 3 trial for tezepelumab, showing an 86% reduction in exacerbation rates in patients with severe asthma and comorbid nasal polyps. This potential first-in-class treatment, targeting thymic stromal lymphopoietin (TSLP), also demonstrated improved lung function and nasal symptom relief. The trial involved 1,061 patients and confirmed tezepelumab's effectiveness irrespective of eosinophil levels, reinforcing its potential for a broad patient population. Safety results showed no significant differences between treatment and placebo groups.
Amgen (NASDAQ:AMGN) will present at Citi's 16th Annual BioPharma Conference on Sept. 8, 2021, at 1:25 p.m. ET. Murdo Gordon, Amgen's executive vice president of Global Commercial Operations, will lead the presentation. The event will be available for live audio streaming for media, investors, and the public via Amgen's website, where it will also be archived for 90 days post-event. Amgen, a biotechnology leader since 1980, focuses on developing innovative therapeutics for serious medical conditions.
Amgen reported Q2 2021 revenues of $6.5 billion, a 5% increase year-over-year, driven by strong unit demand despite lower net selling prices. GAAP EPS fell 73% to $0.81 due to a significant write-off from the Five Prime Therapeutics acquisition, while non-GAAP EPS rose 4% to $4.38. Operating income on a GAAP basis dropped 64% to $0.8 billion, leading to a 25.8 percentage point decrease in operating margin to 13.5%. Free cash flow was $1.7 billion, down from $2.7 billion in Q2 2020. Amgen reaffirmed its total revenue guidance for 2021 at $25.8 to $26.6 billion, while revising GAAP EPS guidance downwards.
Amgen (NASDAQ: AMGN) has declared a $1.76 per share dividend for Q3 2021, set to be paid on September 8, 2021, to stockholders of record by August 17, 2021. This action reflects the company's ongoing commitment to returning value to its shareholders. Amgen continues to focus on developing innovative therapeutics to address unmet medical needs and improve patient health outcomes. The company, established in 1980, is recognized as a leader in biotechnology, striving to advance its pipeline of medicines.
Amgen announced the appointment of S. Omar Ishrak to its Board of Directors, effective immediately. Dr. Ishrak, a seasoned leader with extensive experience in the healthcare sector, will also serve on the Corporate Responsibility and Compliance Committee and the Compensation and Management Development Committee. With this addition, Amgen's Board now comprises 12 directors, 11 of whom are independent. Ishrak previously served as CEO of Medtronic and has held pivotal roles at GE Healthcare. His expertise is expected to enhance Amgen's focus on innovation and patient care.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
